Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Ureteral Neoplasms: Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.Urologic Neoplasms: Tumors or cancer of the URINARY TRACT in either the male or the female.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Kidney Pelvis: The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES.Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Urethral Neoplasms: Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.Urothelium: The epithelial lining of the URINARY TRACT.Cystectomy: Used for excision of the urinary bladder.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Urinary Bladder: A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Administration, Intravesical: The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Urogenital Neoplasms: Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.Uroplakin II: A uroplakin subtype that heterodimerizes with UROPLAKIN IA to form a component of the asymmetric unit membrane found in urothelial cells.Cystoscopy: Endoscopic examination, therapy or surgery of the urinary bladder.Ureter: One of a pair of thick-walled tubes that transports urine from the KIDNEY PELVIS to the URINARY BLADDER.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Liver Neoplasms: Tumors or cancer of the LIVER.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Kidney Neoplasms: Tumors or cancers of the KIDNEY.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Uroplakin III: A uroplakin subtype that heterodimerizes with UROPLAKIN IB to form a component of the asymmetric unit membrane found in urothelial cells.Brenner Tumor: A smooth, solid or cystic fibroepithelial (FIBROEPITHELIAL NEOPLASMS) tumor, usually found in the OVARIES but can also be found in the adnexal region and the KIDNEYS. It consists of a fibrous stroma with nests of epithelial cells that sometimes resemble the transitional cells lining the urinary bladder. Brenner tumors generally are benign and asymptomatic. Malignant Brenner tumors have been reported.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Muscle Neoplasms: Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Uroplakin Ib: A tetraspanin domain-containing uroplakin subtype. It heterodimerizes with UROPLAKIN III to form a component of the asymmetric unit membrane found in urothelial cells.Cell Line, Tumor: A cell line derived from cultured tumor cells.Uroplakin Ia: A tetraspanin domain-containing uroplakin subtype. It heterodimerizes with UROPLAKIN II to form a component of the asymmetric unit membrane found in urothelial cells.Hematuria: Presence of blood in the urine.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.Butylhydroxybutylnitrosamine: A substituted carcinogenic nitrosamine.Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.DNA, Neoplasm: DNA present in neoplastic tissue.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Spermatocele: A cystic dilation of the EPIDIDYMIS, usually in the head portion (caput epididymis). The cyst fluid contains dead SPERMATOZOA and can be easily differentiated from TESTICULAR HYDROCELE and other testicular lesions.Nephrectomy: Excision of kidney.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Papilloma: A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Lung Neoplasms: Tumors or cancer of the LUNG.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.Papilloma, Inverted: A mucosal tumor of the urinary bladder or nasal cavity in which proliferating epithelium is invaginated beneath the surface and is more smoothly rounded than in other papillomas. (Stedman, 25th ed)Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Breast Neoplasms: Tumors or cancer of the human BREAST.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Keratin-7: A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.Chromosomes, Human, Pair 9: A specific pair of GROUP C CHROMSOMES of the human chromosome classification.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.DeoxycytidineFollow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.Pelvic Neoplasms: Tumors or cancer of the pelvic region.Semicircular Ducts: The three membranous semicircular ducts within the bony semicircular canals. They open into the UTRICLE through five openings. Each duct has at one end a sensory area called the ampullary crest. AMPULLARY HAIR CELLS of the crests sense the movement of ENDOLYMPH resulting from rotation of the head.FANFT: A potent nitrofuran derivative tumor initiator. It causes bladder tumors in all animals studied and is mutagenic to many bacteria.Keratin-20: A type I keratin expressed predominately in gastrointestinal epithelia, MERKEL CELLS, and the TASTE BUDS of the oral mucosa.Dog Diseases: Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Genes, p53: Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.RNA, Neoplasm: RNA present in neoplastic tissue.Carcinoma, Embryonal: A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)Time Factors: Elements of limited time intervals, contributing to particular results or situations.Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Mouth Neoplasms: Tumors or cancer of the MOUTH.Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Metaplasia: A condition in which there is a change of one adult cell type to another similar adult cell type.Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.Ploidies: The degree of replication of the chromosome set in the karyotype.Occlusive Dressings: Material, usually gauze or absorbent cotton, used to cover and protect wounds, to seal them from contact with air or bacteria. (From Dorland, 27th ed)Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Epithelium: One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.Vinblastine: Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.Urinary Diversion: Temporary or permanent diversion of the flow of urine through the ureter away from the URINARY BLADDER in the presence of a bladder disease or after cystectomy. There is a variety of techniques: direct anastomosis of ureter and bowel, cutaneous ureterostomy, ileal, jejunal or colon conduit, ureterosigmoidostomy, etc. (From Campbell's Urology, 6th ed, p2654)Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Urologic Surgical Procedures: Surgery performed on the urinary tract or its parts in the male or female. For surgery of the male genitalia, UROLOGIC SURGICAL PROCEDURES, MALE is available.Colonic Neoplasms: Tumors or cancer of the COLON.Transplantation, Heterologous: Transplantation between animals of different species.Carcinoma, Verrucous: A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)Kidney Calices: Recesses of the kidney pelvis which divides into two wide, cup-shaped major renal calices, with each major calix subdivided into 7 to 14 minor calices. Urine empties into a minor calix from collecting tubules, then passes through the major calix, renal pelvis, and ureter to enter the urinary bladder. (From Moore, Clinically Oriented Anatomy, 3d ed, p211)Mitotic Index: An expression of the number of mitoses found in a stated number of cells.Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Cytodiagnosis: Diagnosis of the type and, when feasible, the cause of a pathologic process by means of microscopic study of cells in an exudate or other form of body fluid. (Stedman, 26th ed)Urinary Tract: The duct which coveys URINE from the pelvis of the KIDNEY through the URETERS, BLADDER, and URETHRA.Stomach Neoplasms: Tumors or cancer of the STOMACH.Skin Neoplasms: Tumors or cancer of the SKIN.Genes, Tumor Suppressor: Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.Paraffin Embedding: The infiltrating of tissue specimens with paraffin, as a supporting substance, to prepare for sectioning with a microtome.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Penile Neoplasms: Cancers or tumors of the PENIS or of its component tissues.Polymorphism, Single-Stranded Conformational: Variation in a population's DNA sequence that is detected by determining alterations in the conformation of denatured DNA fragments. Denatured DNA fragments are allowed to renature under conditions that prevent the formation of double-stranded DNA and allow secondary structure to form in single stranded fragments. These fragments are then run through polyacrylamide gels to detect variations in the secondary structure that is manifested as an alteration in migration through the gels.Rats, Inbred F344Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Paclitaxel: A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Papillomaviridae: A family of small, non-enveloped DNA viruses infecting birds and most mammals, especially humans. They are grouped into multiple genera, but the viruses are highly host-species specific and tissue-restricted. They are commonly divided into hundreds of papillomavirus "types", each with specific gene function and gene control regions, despite sequence homology. Human papillomaviruses are found in the genera ALPHAPAPILLOMAVIRUS; BETAPAPILLOMAVIRUS; GAMMAPAPILLOMAVIRUS; and MUPAPILLOMAVIRUS.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Chromosome Aberrations: Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Schistosomiasis: Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Microsatellite Repeats: A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)Karyotyping: Mapping of the KARYOTYPE of a cell.Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Lymph Node Excision: Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Carcinogens: Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.Embryonal Carcinoma Stem Cells: The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.In Situ Hybridization: A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Cyclooxygenase 2: An inducibly-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes and INFLAMMATION. It is the target of COX2 INHIBITORS.Mucous Membrane: An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.Carcinoma, Papillary, Follicular: A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.Receptor, Epidermal Growth Factor: A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.Mice, Inbred BALB CGallbladder Neoplasms: Tumors or cancer of the gallbladder.Urine: Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Papillomavirus Infections: Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.alpha-Fetoproteins: The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.Tongue Neoplasms: Tumors or cancer of the TONGUE.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Blotting, Northern: Detection of RNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Vascular Endothelial Growth Factor A: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Chromosome Disorders: Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats. (1/1469)

Three transitional cell carcinomas induced in Fischer 344 rats by a methylcholanthrene pellet or a foreign body inserted locally into the bladder have been serially transplanted in the syngeneic strain for up to 6.5 years. There have been no changes in the individual morphological characteristics of the tumors during this time. Cells cultured in vitro for varying numbers of passages reproduce regularly the morphology of each tumor when they are injected back into the animals and results from a microcytotoxicity assay for cellular immunity indicate that they retain a common, bladder tumor-specific antigen. These tumors are useful for research in turmo biology and are offered to other scientists seeking transplantable carcinomas for experimentation.  (+info)

Natural history of papillary lesions of the urinary bladder in schistosomiasis. (2/1469)

Variable epithelial hyperplasia was observed in urinary bladder of nine capuchin monkeys (Cebus apella) when examined at cystotomy 94 to 164 weeks after infection with Schistosoma haematobium. These hosts were followed for 24 to 136 weeks postcystotomy to determine the status of bladder lesions in relation to duration of infection and to ascertain whether lesion samples removed at cystotomy reestablished themselves in autologous and heterologous transfers. There was involution of urothelial hyperplasia in eight of nine animals and no evidence for establishment of transplanted bladder lesions.  (+info)

Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. (3/1469)

The Mdm2 protein is frequently overexpressed in human non-seminomatous germ cell tumours and transitional carcinoma of the bladder where it may contribute to tolerance of wtp53. Mdm2 forms an autoregulatory feedback loop with p53; the Mdm2 gene is responsive to transactivation by p53 and once synthesized the Mdm2 protein terminates the p53 response. We show here that the topoisomerase poison etoposide, like ultra violet irradiation, inhibits Mdm2 synthesis. Cytotoxic concentrations of etoposide (IC90 for > 3 h) result in inhibition of Mdm2 induction at both the RNA and protein level. Rapid apoptosis ensues. Global transcription is not inhibited: p21waf-1/cip1 and GADD45 expression increase in a dose dependent manner. Inhibition of Mdm2 synthesis depends on the continuous presence of etoposide, suggesting the DNA damage may prevent transcription. Downregulation of Mdm2 transcript occurs in cells expressing HPV16-E6 suggesting that inhibition of Mdm2 transcription is p53-independent. When cells are -treated with a pulse (1 h) of etoposide and reincubated in drug free medium, Mdm2 synthesis commences immediately after damage is repaired (3 h) and the p53 response is attenuated. Induction of apoptosis and loss of clonogenicity are 3-5-fold lower under pulse treatment conditions. This is the first observation of inhibition of Mdm2 transcription following treatment with topoisomerase (topo II) poisons, a feature that may be useful in tumour types where p53 is tolerated by overexpression of Mdm2.  (+info)

Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. (4/1469)

Interleukin (IL)-10 is a potent immunosuppressive cytokine that has been found to be present at the tumor site in a wide variety of human cancers, including transitional cell carcinoma of the bladder. Using a murine bladder tumor (MB49), which we show to express the male transplantation antigen (HY), we tested the hypothesis that IL-10 at the tumor site can block the generation of a tumor-specific type 1 immune response. We show that, despite its expression of HY, MB49 fails to prime for an HY-specific type 1 (IFN-gamma) response in normal female mice. Although MB49 does not constitutively produce IL-10, our data support a model whereby MB49 induces infiltrating cells to produce IL-10. This feature rendered the IL-10 knockout (KO) mouse, whose infiltrating cells are incapable of IL-10 production, a suitable model in which to study MB49 in the absence of IL-10. When injected into IL-10 KO mice, MB49 does prime for an HY-specific, type 1 immune response. Furthermore, IL-10 KO mice show prolonged survival and an increased capacity to reject tumors as compared with normal mice. We also tested the ability of tumor-induced IL-10 to inhibit immunization to a non-tumor antigen present at the tumor site. When vaccinia virus encoding beta-galactosidase (beta-gal) is injected into the tumors of normal mice, no beta-gal-specific IFN-gamma response is mounted. However, when this same viral construct is injected into the tumors of IL-10 KO mice, it produces a strong beta-gal-specific, IFN-gamma response. These studies demonstrate that tumor-induced IL-10 can block the generation of a tumor-specific type 1 immune response as well as subvert attempts to elicit a type 1 immune response to a non-tumor antigen at the tumor site.  (+info)

Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. (5/1469)

Epidermal growth factor receptor (EGFR) regulates the growth and progression of human transitional cell carcinoma (TCC) of the bladder. We have shown that therapy targeting EGFR inhibited the growth of human TCC established orthotopically in nude mice. The purpose of this study was to evaluate whether EGFR-directed therapy affects angiogenesis associated with the growth and metastasis of human TCC. We determined the cytostatic effect and the effect on production of angiogenic factors after in vitro treatment of the human TCC cell line 253J B-V with MAb C225, a chimerized monoclonal anti-EGFR antibody. The 253J B-V cells were implanted orthotopically into athymic nude mice, and established tumors (4 weeks) were treated with i.p. MAb C225. Expression of the angiogenic factors vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF) was evaluated by immunohistochemistry and in situ mRNA hybridization analyses and correlated with microvessel density evaluated after immunohistochemical staining with anti-CD31. In vitro treatment with MAb C225 inhibited mRNA and protein production of VEGF, IL-8, and bFGF by 253J B-V cells in a dose-dependent manner. MAb C225 therapy of nude mice with established TCCs growing orthotopically resulted in inhibition of growth and metastasis compared with controls (P <0.0005). VEGF, IL-8, and bFGF expression was significantly lower in treated tumors than in controls. The down-regulation of these angiogenic factors preceded the involution of blood vessels. These studies indicate that therapy with anti-EGFR MAb C225 has a significant antitumor effect mediated, in part, by inhibition of angiogenesis.  (+info)

Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder. (6/1469)

Transitional cell carcinoma of the bladder is one of the human cancers most responsive to immunotherapy, and local interleukin-2 (IL-2) production appears to be an important requirement for immunotherapy to be effective. In this study, we engineered two human bladder cancer cell lines (RT112 and EJ) to constitutively release human IL-2 by retroviral vector-mediated gene transfer. Following infection and selection, stable and consistent production of biologically active IL-2 was demonstrated at both the mRNA and the protein level. Morphology, in vitro growth rate and proliferation, as well as other cytokine gene mRNA or membrane adhesion receptor expression, were not altered in IL-2 transduced cells as compared to their parental or control vector-infected counterparts. Moreover, IL-2 engineered cells lost their tumorigenicity into nu/nu mice and the mechanism of rejection appeared to involve multiple host effector cell populations, among which a prominent role was played by neutrophils and radiosensitive cells. These findings may offer support to the development of an IL-2-based gene therapy approach to human bladder cancer.  (+info)

Urinary bladder transitional cell carcinogenesis is associated with down-regulation of NF1 tumor suppressor gene in vivo and in vitro. (7/1469)

The NF1 gene product (neurofibromin) is known to act as a tumor suppressor protein by inactivating ras. The best documented factors involved in urinary bladder transitional cell carcinoma (TCC) are ras proto-oncogene activation and p53 suppressor gene mutations. This is the first study reporting alterations in NF1 gene expression in TCC. We examined NF1 gene expression in a total of 29 surgical urinary bladder TCC specimens representing grades 1 to 3 and in three cell lines, RT4, 5637, and T24 (representing grades 1 to 3, respectively). Decreased NF1 gene expression was observed in 23 of 29 (83%) TCC specimens as estimated by immunohistochemistry, the decrease being more pronounced in high-grade tumors. NF1 mRNA levels were markedly lower in TCC tissue compared with adjacent non-neoplastic urothelium, as studied by in situ hybridization for grade 3 TCC. Immunohistochemistry and Western blotting demonstrated that TCC cell lines expressed NF1 protein at different levels, expression being almost undetectable in T24 (grade 3) cells. Northern blotting for cell lines demonstrated reduced NF1 mRNA levels in grade 3 TCC cells. Reverse transcription polymerase chain reaction for cell lines and selected grade 2 and grade 3 tissue samples demonstrated NF1 type II mRNA isoform predominance in all samples studied. Our results show that both NF1 mRNA and protein levels are decreased in high-grade TCC, suggesting that alterations of NF1 gene expression may be involved in bladder TCC carcinogenesis.  (+info)

Overexpression of the wild type p73 gene in human bladder cancer. (8/1469)

p73, a first p53 relative, was recently identified and shown to be monoallelically expressed in a number of different human tissues. To determine the potential role of this gene in human bladder cancer, we investigated p73 expression levels, allelic expression patterns, and analysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and in seven bladder cancer cell lines. In a comparison between normal and tumor tissues using quantitative RT-PCR analysis, we found that p73 was overexpressed in 22/23 bladder cancers, sometimes as great as 20-fold. Allelic expression analysis using a C/T polymorphism in exon 2 and a newly identified T/C polymorphism in exon 5 revealed that p73 was biallelically expressed in both normal bladder and cancer tissues, suggesting that p73 is not imprinted in bladder tissue. Mutation screening of the p73 gene in bladder cancer DNAs using denaturing high-performance liquid chromatography analysis and DNA sequencing revealed no tumor-specific mutations in any coding exons of the p73 gene. These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer.  (+info)

Congratulations! You have found the Transitional cell carcinoma Forum on Forum Jar. This forum is a place where people who are interested in Transitional cell carcinoma come together and discuss about Transitional cell carcinoma. Please use the message board below to post anything related to Transitional cell carcinoma . If you are interested in other similar forums, please check out the Related Forums section on the right. If you like this forum, please dont forget to tell your friends about Forum Jar ...
TY - JOUR. T1 - Transitional cell carcinoma of the renal pelvis with chriocarcinomatous differentiation. Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder. AU - Grammatico, Dino. AU - Grignon, David J.. AU - Eberwein, Parker. AU - Shepherd, R. Roderick. AU - Hearn, Stephen A.. AU - Walton, John C.. PY - 1993/3/1. Y1 - 1993/3/1. N2 - Background. There have been 12 documented cases of choriocarcinoma arising in the urinary bladder, either alone or in combination with other epithelial tumors. It has been shown that some high‐grade transitional cell carcinomas (TCC), without obvious syncytiotrophoblastic elements, can produce human chorionic gonadotropins (HCG). Methods. A case of choriocarcinoma, in association with high‐grade TCC of the renal pelvis, was encountered in an 80‐year‐old man. For additional evaluation of HCG production by TCC, 25 consecutive cases of invasive ...
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
Welcome to the Pathology Education Informational Resource (PEIR) Digital Library, a multidisciplinary public access image database for use in medical education. ...
Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. Papillary transitional cell carcinomas (Ta tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ, CIS), frequently progress to invasive disease. We examined 216 bladder tumors of various stages and histopathologies for two genetic alterations previously described to be of importance in bladder tumorigenesis. Loss of heterozygosity of chromosome 9 was observed in 24 of 70 (34%) Ta tumors but was present in only 3 of 24 (12%) CIS and dysplasia lesions (P = 0.04). In contrast, only 1 of 36 (3%) Ta tumors contained a p53 gene mutation compared to 15 of 23 (65%) CIS and dysplasias (P , 0.001), a frequency comparable to that observed in muscle invasive tumors (25 of 49; 51%). The presence of p53 mutations in CIS and dysplasia could explain their propensities to progress since these mutations are known to ...
Noninvasive transitional cell carcinomas of the bladder can have two distinct morphologies suggesting they contain different genetic alterations. Papillary transitional cell carcinomas (Ta tumors) are often multifocal and only occasionally progress, whereas flat tumors (carcinomas in situ, CIS), frequently progress to invasive disease. We examined 216 bladder tumors of various stages and histopathologies for two genetic alterations previously described to be of importance in bladder tumorigenesis. Loss of heterozygosity of chromosome 9 was observed in 24 of 70 (34%) Ta tumors but was present in only 3 of 24 (12%) CIS and dysplasia lesions (P = 0.04). In contrast, only 1 of 36 (3%) Ta tumors contained a p53 gene mutation compared to 15 of 23 (65%) CIS and dysplasias (P , 0.001), a frequency comparable to that observed in muscle invasive tumors (25 of 49; 51%). The presence of p53 mutations in CIS and dysplasia could explain their propensities to progress since these mutations are known to ...
TY - JOUR. T1 - Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract. AU - Thompson, R. Houston. AU - Krambeck, Amy. AU - Lohse, Christine M.. AU - Elliott, Daniel S.. AU - Patterson, David E.. AU - Blute, Michael L.. PY - 2008/11. Y1 - 2008/11. N2 - OBJECTIVE: To report our experience using ureteroscopic or percutaneous management of upper urinary tract (UUT) transitional cell carcinoma (TCC) in patients with no history of bladder TCC. PATIENTS AND METHODS: Between 1983 and 2004 we identified 22 patients who underwent endoscopic management of TCC first diagnosed in the UUT and in the setting of a normal contralateral kidney. We performed a retrospective chart review and conducted outcome analyses. RESULTS: The median (range) age at diagnosis was 64 (37-86) years and the median tumour size was 0.8 (0.3-2.6) cm. The tumour grade was 1, 2, or diagnosed as visual low grade in two (9%), seven (32%), and 13 (59%) patients, respectively; no patient ...
Transitional cell carcinoma is cancer of the urothelium, the lining of the urinary tract. In the bladder this cancer is referred to as bladder cancer. When it occurs in the ureter or renal pelvis it is caller upper tract transitional cell carcinoma (UT-TCC). These cancers are rare compared to bladder cancer. In certain instances they can be treated endoscopically with ureteroscopic fulguration or laser ablation. More commonly they require surgical removal. Surgery may precede or follow systemic chemotherapy. When UT-TCC occurs in the lower part of the ureter near the bladder, it may be possible to remove only the affected part of the ureter (distal ureterectomy). Likewise UT-TCC in the middle or upper ureter may possibly be treated with subtotal or total ureterectomy. All these approaches require urinary tract reconstruction consisting of ureteral reimplantation, with or without a psoas hitch, Boari flap, ileal ureter, or autotransplantation of the kidney. When UT-TCC affects the renal pelvis or ...
history of serious or concurrent illness or uncontrolled medical disorder; any medical condition that might be aggravated by treatment or which could not be controlled: active infection requiring antibiotics within 2 weeks before the study inclusion, unstable diabetes mellitus, uncontrolled hypercalcaemia ,2.9 mmol/L (or ,G2 NCI CTCAE v4.0), concurrent congestive heart failure NYHA (class III-IV) or any type of angina pectoris and/or a diagnosis of myocardial infarction during the previous 6 months and/or poorly controlled hypertension will be excluded, QTc ,450 ms at baseline, additional risk factors for Torsade de Pointes (heart failure and hypokalemia (≥G1, i.e. P-K ,LLN-2.5 mM) or family history of long QT-syndrome), cardiac arrhythmias requiring anti-arrhythmics (excluding beta-blockers or digoxin for chronic atrial fibrillation ...
TY - JOUR. T1 - The management of stage T1 grade 3 transitional cell carcinoma of the bladder. AU - Evans, Christopher P. AU - Busby, J. E.. PY - 2003/9. Y1 - 2003/9. KW - BCG. KW - Cystectomy. KW - Superficial bladder cancer. KW - Transitional cell carcinoma. UR - http://www.scopus.com/inward/record.url?scp=0041910054&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0041910054&partnerID=8YFLogxK. U2 - 10.1046/j.1464-410X.2003.04357.x. DO - 10.1046/j.1464-410X.2003.04357.x. M3 - Article. C2 - 12930415. AN - SCOPUS:0041910054. VL - 92. SP - 345. EP - 348. JO - BJU International. JF - BJU International. SN - 1464-4096. IS - 4. ER - ...
Incidence and Mortality Transitional cell carcinoma of the renal pelvis, accounting for only 7% of all kidney tumors, and transitional cell cancer of the ureter, accounting for only 1 of every 25 upper tract tumors, are curable in more than 90% of patients if they are superficial and confined to the renal pelvis or...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
A nine-year-old chemically neutered male hovawart was referred due to dysuria, stranguria, haematuria and inappetence. Initial examinations suggested a transitional cell carcinoma of the urinary bladder with pulmonary metastases and ureteral ectopia. To confirm the diagnosis and rule out possible ureteral ectopia, cystoscopy was performed. Transitional cell carcinoma was confirmed, and a urethral foreign body was revealed. After successful removal, the foreign body turned out to be a 17-cm long piece of a urinary catheter. The dogs clinical signs ceased completely a few days after extraction of the foreign object and palliative therapy with meloxicam. Approximately four weeks later its condition deteriorated and the owner elected euthanasia. ...
Highlights: Black-Right-Pointing-Pointer The tumor suppressor gene PDCD4 is down-regulated in many tumorous entities. Black-Right-Pointing-Pointer We investigate the impact of PDCD4 and its regulating factor miR-21 in urothelial carcinoma. Black-Right-Pointing-Pointer We confirm PDCD4 as a tumor suppressor gene and it could be a diagnostic marker for this tumor. -- Abstract: Background: We investigated the role of the programmed cell death 4 (PDCD4) tumor suppressor gene in specimens of transitional cell carcinoma and of healthy individuals. Methods: PDCD4 immunohistochemical expression was investigated in 294 cases in histologically proven transitional cell carcinoma in different tumorous stages (28 controls, 122 non-muscle invasive urothelial carcinoma, stages Tis-T1, 119 invasive transitional cell carcinoma stages T2-T4 and 25 metastases). MiR-21 expression, an important PDCD4 regulator, was assessed with real-time PCR analysis and showed inverse correlation to tissue PDCD4 expression. ...
View details of top transitional cell carcinoma hospitals in Thane. Get guidance from medical experts to select best transitional cell carcinoma hospital in Thane
This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Transitional cell cancer of the renal pelvis and ureter is a disease in which malignant (cancer) cells form in the renal pelvis and ureter. The renal pelvis is the top part of the ureter. The ureter is a long tube that connects the kidney to the bladder. There are two kidneys, one on each side of the backbone, above the...
The Report Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2014 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
The recent study by Rosenberg et al in The Lancet-summarized in this issue of The ASCO Post-is a very important paper in the field of bladder cancer therapy.1 It is the first phase II trial in metastatic transitional cell carcinoma that demonstrates the single-agent activity of the investigational programmed cell death ligand 1 (PD-L1) antibody atezolizumab.. Based on objective response rate and low level of toxicity, atezolizumab appears to be superior to all other current single agents used in second-line therapy for transitional cell carcinoma. Moreover, the trial reported by Rosenberg et al strongly confirms the activity of atezolizumab seen in the phase Ib trial of Powles et al.2. Concordant Studies. In the phase Ib trial, patients were initially selected for entry based on PD-L1 expression of 2 to 3+ on the infiltrating immune cells (IC 2/3) in the tumor (not PD-L1 expression on the tumor cells). A subsequent group of patients with IC 0/1 disease were entered on the trial. In the selected ...
Learn more about Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®) (Patients) from the National Cancer Institute at Siteman Cancer Center.
Abstract of Paper: Role of P27 (Kip 1) and MUC1 in Papillary Transitional Cell Carcinoma of the Urinary Bladder , Author: TAGHREED A. ABD EL-AZEEZ, M.D.*; ABD EL-LATEF M. EL-BALSHY, M.D.*, MAGDY EL-TABYE, M.D.** and ADEL Z. ELSAEDY, M.D.* The Departments of Histopathology* and Urosurgery**, Faculty of Medicine, Benha University, Egypt , Year: 2008 , Faculty of Medicine, Benha University
The nested variant of transitional cell carcinoma (TCC-NV) is a rare neoplasm; only eight cases have been described. This report reviews the clinicopathologic features of 16 additional examples. The cases were collected from consultations received during a 13-year period. In most instances, a consultation was sought because the histologic features suggested an atypical proliferation of Brunns nests or a lesion similar to the previously published examples of TCC-NV. Clinical data were gathered and tissues were studied to exclude prostatic cancer and adenocarcinoma. TCC-NV is characterized by the presence of irregular nests and/or tubules of transitional cells infiltrating the lamina propria without surface involvement. Neoplastic cells tend to have innocuous features but at least a few cells in every case are cytologically anaplastic. There is a marked male predominance. Synchronous or metachronous TCCs of more usual histologic make-up may occur. After a follow-up averaging 16.6 months, only three
TY - JOUR. T1 - Germline translocation t(5;20)(p15;q11) and familial transitional cell carcinoma. AU - Schoenberg, Mark. AU - Kiemeney, Lambertus. AU - Walsh, Patrick C.. AU - Griffin, Constance A.. AU - Sidransky, David. PY - 1996/3. Y1 - 1996/3. KW - bladder. KW - carcinoma, transitional cell. KW - heterozygote detection. KW - translocation (genetics). UR - http://www.scopus.com/inward/record.url?scp=0030049893&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0030049893&partnerID=8YFLogxK. U2 - 10.1016/S0022-5347(01)66380-8. DO - 10.1016/S0022-5347(01)66380-8. M3 - Article. C2 - 8583556. AN - SCOPUS:0030049893. VL - 155. SP - 1035. EP - 1036. JO - Journal of Urology. JF - Journal of Urology. SN - 0022-5347. IS - 3. ER - ...
TY - JOUR. T1 - Transitional cell carcinoma of the prostate. AU - Matzkin, H.. AU - Soloway, M. S.. AU - Hardeman, S.. PY - 1991/1/1. Y1 - 1991/1/1. KW - Carcinoma. KW - Prostatic neoplasms. KW - Transitional cell. UR - http://www.scopus.com/inward/record.url?scp=0026346052&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0026346052&partnerID=8YFLogxK. U2 - 10.1016/S0022-5347(17)38047-3. DO - 10.1016/S0022-5347(17)38047-3. M3 - Review article. C2 - 1942262. AN - SCOPUS:0026346052. VL - 146. SP - 1207. EP - 1212. JO - Journal of Urology. JF - Journal of Urology. SN - 0022-5347. IS - 5. ER - ...
BACKGROUND In this study we used histopathological examinations performed over a 20-year period to describe the characteristics of newly diagnosed transitional cell carcinoma (TCC) of the bladder in relation to patient age, and to verify changes in the TCC over different periods of observation or in relation to patient age. METHODS We reviewed all histopathological examinations performed from January 1979 to December 1998 in patients undergoing surgery who were newly diagnosed with TCC of the bladder. All examinations were performed by the same pathologist and reviewed by two pathologists. In each case analyzed, we evaluated T classification of the tumor, histological grade, size, localization, growth type, multiplicity and carcinoma in situ (CIS). RESULTS The study population included 3113 men and 620 women. The mean patient age was 66.31 +/- 10.84 years. A high percentage of Ta (52.2%) and T1 (27.7%) tumors were found. The number of cases observed and, in particular, the percentage of Ta tumors
Trial Specifics. This trial is designed to evaluate the safety and preliminary pain management and effect of a novel therapy in dogs with bladder transitional cell carcinoma (TCC). A secondary goal is to assess potential anti-cancer effect. The trial involves one-time treatment administered directly into the bladder using a urinary catheter. Dogs may receive a second treatment one month after enrollment if warranted. The treatment will be administered under sedation or general anesthesia. There is no placebo in this trial. An estimated 15 client-owned dogs with will be enrolled. Owners will be required to complete quality of life surveys, collect a daily urine sample for visual analysis, and record the urine collection results in a provided journal. The trial site will train the owners on collection and evaluation techniques. Trial visits include the dogs initial consultation, treatment day (Day 0), and then recheck visits on Days 7, 14, 28, 56, and 84. Anti-cancer therapies must be ...
|b|Objectives:|/b| To determine if detection of cytokeratin 20 (CK20) gene expression, by reverse transcriptase-polymerase chain reaction (RT-PCR) in urine from transitional cell carcinoma
Misdiagnosis of Transitional cell carcinoma including hidden diseases, diagnosis mistakes, alternative diagnoses, differential diagnoses, and misdiagnosis.
Treatments for Transitional cell carcinoma including drugs, prescription medications, alternative treatments, surgery, and lifestyle changes.
Video articles in JoVE about t lymphocytes cytotoxic include A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses, A Colorimetric Assay that Specifically Measures Granzyme B Proteolytic Activity: Hydrolysis of Boc-Ala-Ala-Asp-S-Bzl, Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes, Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT, Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice, Analysis of Simian Immunodeficiency Virus-specific CD8+ T-cells in Rhesus Macaques by Peptide-MHC-I Tetramer Staining, Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development, A Flow Cytometry-Based Cytotoxicity Assay for the Assessment
CELMA DOMENECH, A. et al. Transitional cell carcinoma relapse in uretero-ileal conduit after radical cistectomy. Actas Urol Esp [online]. 2008, vol.32, n.6, pp.642-644. ISSN 0210-4806.. Transitional cell carcinoma relapse in ileal conduit after radical cistectomy is a rare event, especially without upper urinary tract involvement. We describe a case of uretero-ileal transitional cell tumour five years after cistectomy for invasive urothelial tumour. Patient underwent endoscopic treatment with good results after 13 months of follow-up.. Palabras clave : Ileal conduit; Urothelium cancer; Endoscopic treatment. ...
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra). Location: University of Rochester Medical ...
The median age of patients was 69 years (range, 40-84 years); 70% were male; 85% were white; all had an Eastern Cooperative Oncology Group performance status of 0 (32%) or 1; 90% had visceral metastases, including 40% with liver metastases; and 67% had pure transitional cell carcinoma histology and 33% had transitional cell carcinoma with other histologic variants. Nectin-4 expression was detected in all 120 patients tested with a trial assay. The median number of prior systemic therapies was three (range, 1-6). Overall, 46% received a prior PD-1 inhibitor, 42% had a prior PD-L1 inhibitor, and 13% received both; 66% received prior cisplatin-based regimens, 26% received prior carboplatin-based regimens, and 8% received both.. The objective response rate on blinded independent central review using Response Evaluation Criteria in Solid Tumors, version 1.1, was 44% (95% confidence interval [CI] = 35%-53%), with a complete response rate of 12%. The estimated median response duration was 7.6 months ...
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern.: A small percentage of ovarian neoplasm
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
By far the most common is transitional cell carcinoma. It starts in the urothelial cells that line the bladder wall and the ureters, which are the tubes that transport urine from the kidneys to the bladder. Transitional cell carcinoma can be low-grade or high-grade, and it can be superficial or invasive. The latter type means the cancer has begun to invade the muscle wall of the bladder or has spread to lymph nodes or nearby organs.. Rarer types of bladder cancer include squamous cell carcinoma and adenocarcinoma, each of which begins in other tissues and cells in the bladder. Small-cell carcinoma, like small-cell carcinoma of the lung, can also grow in the bladder.. ...
The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.
The median p53 and MIB-1 indices were 45.2% and 30.3%, respectively. The median follow-up was 4.5 years (range, 0.1-10 years). There were no statistically significant associations noted between the p53 and MIB-1 indices and the outcomes studied. When the analysis was limited to patients who were treated with adjuvant chemotherapy (n = 37 patients), the p53 index was found to have no prognostic value; however, there was a significant association between MIB-1 and distant metastases (P = 0.049). When disease-specific survival rates were stratified according to p53 index and chemotherapy, patients exhibited a response to chemotherapy regardless of p53 index. ...
CT is of limited value in staging low-grade disease because it cannot accurately depict the depths of tumoral invasion. Therefore, stages Ta-T2 cannot be distinguished. The strength of CT lies in the ... more
Dr. Daniel Goldstein reviews trial results comparing nab-paclitaxel to standard paclitaxel in second line treatment of bladder cancer, comparing these results to those in breast cancer and raising questions of utility in pancreatic cancer. - Bladder Cancer
The patient was followed with periodic ultrasounds and there is no evidence of tumor in bladder or in upper urinary tract after 5 years of follow-up.. Discussion. Bladder transitional-cell carcinoma is extremely rare in the first two decades of life. The estimated frequency in patients under 40 is less than 1% in all cases (Khaisidy et al., 1990).. Previous history of exposure to carcinogenic agents; such as smoking, chemotherapy or radiation are well-known risk factors for bladder cancer in adults (Perez Niño el al. 2009). However, the prior exposure to toxic substances is not normally found in young patients. (Hoening et al. 1996; Khaisidy et al. 1990; Perez Niño et al. 2009; Ruiz et al. 2009, Paner et al. 2011; Giedl el al. 2006). A significant association was found between urothelial tumors and a mutation in the p53 gene. In adults, this mutation is observed in highly differentiated and aggressive tumors, whereas in young people it is also present in low-grade tumors. A study by Linn et ...
Learn how we customize treatment for urologic cancers for each patient, based on the type & stage of cancer, and each patients physical health & age.
Malrotated kidneys are affected by the same conditions as a normally rotated kidney with increased risk of PUJ obstruction, urinary stasis and urolithiasis.
We have identified over 20 different medical factors that might potentially confound our study on aging, such as race, blood pressure, diabetes, type or size of tumor adjacent to the normal section etc (supplemental Table 1). Fourteen medical factors affected less than ten patients (such as diabetes or proteinuria), making it unlikely that they could account for age-related change in gene expression in the 74 patients analyzed. Six medical factors occurred in ten or more patients (race, two types of tumors, size of tumor and hypertension), but it is unlikely that these affect our aging study for the following reasons. First, with the exception of transitional cell carcinoma, none of the other medical factors were skewed with respect to age, and would not be expected to bias gene expression in an age-related fashion (Supplemental Figure 1). Second, the nephrectomies contained renal cell carcinoma and transitional cell carcinoma that were localized to an isolated region of the kidney. Our normal ...
Another name for Cancer Ureter is Transitional Cell Carcinoma. The evaluation of transitional cell carcinoma begins with a medical history and physical ...
Another name for Malignant Neoplasm of the Ureter is Transitional Cell Carcinoma. The cause of transitional cell carcinoma is unknown, but genetics may ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
The most common sonographic appearance of TCC is that of a hypoechoic mass in the renal collecting system that splits the central echocomplex with varying degrees of infundibular dilatation. Focal hyp... more
The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format. By default, clicking on the export buttons will result in a download of the allowed maximum amount of items. To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export. After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format. ...
Heres todays case. Its an 11-year-old female neutered Golden Retriever with a two-month history of straining to urinate. She also has a lameness of the right pelvic limb for 1 week. … [Read more...] ...
Plasmacytoid carcinoma of the urinary bladder or plasmacytoid urothelial carcinoma (PUC) is a rare and only recently described histological variant of transitional cell carcinoma (TCC). We herein report the clinical and histopathological features for
Established from the transitional cell carcinoma (histological grade G2) excised from a woman (age unknown) with untreated primary urinary bladder carcinoma in 1973; described to form tumors in nude mice. Cytokeratine (4),5,(6), 7, 8, 13, 17, 18, 19, Desmoplakin; DNA-index=2,1 ...
The 12 cases of urological malignancies included one case of renal cell carcinoma, one case of transplanted kidney carcinoma, two cases of bilateral pelvic transitional cell carcinoma (TCC), three cases of unilateral pelvic TCC, one case of bilateral ureter TCC, one case of unilateral ureter TCC, and three cases of bladder TCC ...
Stone surgery, stone prevention and metabolic testing, laser prostatectomy / HOLEP, general urology including penoscrotal work, lasering of bladder TCC - transitional cell carcinoma under local anaesthetic, complex endourology ...
Around 9,000 people in the UK (more men than women) are diagnosed with kidney cancer every year. This number is slowly increasing, possibly because other scans are detecting tumours that would otherwise have been unrecognised.. 90% of kidney cancers are renal cell cancers - tumours in the small tubes within the kidney substance. Transitional cell cancers start in the renal pelvis lining (the part of the kidney that collects the urine and transports it towards the bladder).. Less common kidney cancers include papillary and collecting duct renal cancer.. ...
Bladder Cancer found in: Dog Bladder Tumor, Dog Bladder Cancer, Cat Bladder Tumor, Dog Prostate Cancer, Cat Prostate Cancer, Cat Common Cancers, Dog Common Cancers, Dog Transitional Cell Carcinoma, Cat Prostatic Tumor, Dog..
MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / physiology. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Chi-Square Distribution. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy ...
Hi, Im new to the forum. My husband was recently diagnosed with PT2 muscle invasive high-grade transitional cell carcinoma with carcinomas in situ. The...
My 74 year old husband was diagnosed with small cell bladder cancer on Aug 14 and started chemo on Aug 17. He had been hospitalized for 12 days when I brought...
According to this article from the Scottish Terrier Club of America, if you have never lost a Scottish Terrier to bladder cancer - or, more properly, Transitional Cell Carcinoma - consider yourself extremely lucky. Research has suggested that Scottish Terriers are 20 times more likely to get bladder cancer than other breeds and it usually occurs in older dogs (average age 11 years). Such a diagnosis can be devastating to dogs and their owners alike. So you .... Continue Reading → ...
一位55歲男性病人,因排尿不順被診斷為良性攝護腺肥大,在進行攝護腺切割手術前,進行電腦斷層檢查時,發現右側腎臟長了10公分的腫瘤,最後診斷為原發性腎臟癌…… 什麼是腎臟癌 所有從腎臟部位發生的惡性腫瘤都可稱做腎臟癌。最常發生在成年人身上的腎臟癌是腎細胞癌(renal cell carcinoma,簡稱RCC)約佔85%,另一種是腎盂癌(Transitional Cell Carcinoma,簡稱TCC)通常影響腎盂,還有肉瘤或轉移性腫瘤等少見的腎臟癌,此外,常發生在兒童身上的腎臟癌是腎母細胞瘤(Nephroblastoma或Wilms tumor)。無論任何年齡都可能會發生腎臟癌,男女發生比例約為5:1,尤其是超過40歲以後,腎臟
by Julia M. Grassinger,Sophie Merz,Heike Aupperle-Lellbach,Hanna Erhard and Robert Klopfleisch Vet. Sci. 2019, 6(1), 31; Published: 19 March 2019 doi.org/10.3390/vetsci6010031 www.mdpi.com/journal/vetsci/special_issues/comparative_oncology Abstract The presence of BRAF variant V595E, as well as an increased cyclooxygenase-2 (COX-2) expression in canine transitional cell carcinoma (TCC) are well-described in the literature. The aim of the present study was to investigate the correlation between breed (terrier versus non-terrier dogs), histological grade, COX-2 expression, and BRAF mutation in canine TCC. Therefore, transmural TCC biopsies from 65 dogs (15 terriers, 50 non-terriers) were graded histologically into low- and high-grade. Immunohistochemical evaluation of the intensity of COX-2 expression was performed using an immunoreactive score (IRS). Exon 15 of chromosome 16 was examined for the BRAF variant c.1799T,A by TaqMan® SNP assay. TCC was low-grade in 20 cases (one terrier, 19 ...
para-Benzoquinone dioxime was tested for carcinogenicity at two dose levels in mice and rats by oral administration. No significant increase in the number of neoplasms was observed in male rats; but in females given the high dose, a significant increase in the number of transitional-cell papillomas and carcinomas of the urinary bladder occurred. In mice, no carcinogenic effect was observed.. No data were available to assess the mutagenicity or teratogenicity of this compound. ...
abstract = "Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the gold-standard therapy for upper-tract cancers. However, less invasive alternatives have a role in the treatment of this disease. Endoscopic management of upper-tract TCC is a reasonable strategy for patients with anatomic or functional solitary kidneys, bilateral upper-tract TCC, baseline renal insufficiency, and significant comorbid diseases. Select patients with a normal contralateral kidney who have small, low-grade lesions might also be candidates for endoscopic ablation. Distal ureterectomy is an option for patients with high-grade, invasive, or bulky tumors of the distal ureter not amenable to endoscopic management. In appropriately selected patients, outcomes following distal ureterectomy are similar to that of radical nephroureterectomy. Bladder cancer is a common occurrence ...
OBJECTIVES: To establish whether high microsatellite instability (MSI) (present in almost 20% of cases) and loss of MSH2 protein expression (sometimes used to predict MSI status) are prognostic factors of overall survival for patients with invasive upper urinary tract transitional cell carcinoma (UUT-TCC). UUT-TCC has a poor prognosis (overall survival less than 50% at 5 years). METHODS: The files of 80 patients who underwent nephroureterectomy for invasive UUT-TCC (Stage pT2 or worse) between 1990 and 2002 were reviewed. The following data were collated: age at diagnosis, prior history of cancer, tobacco consumption, tumor stage and grade, and disease progression. MSI was determined by polymerase chain reaction/fragment analysis and MSH2 protein expression by immunohistochemistry on retrieved tumor tissue. RESULTS: The median patient age was 71.5 years. The male/female ratio was 2.8. High MSI and loss of MSH2 expression were encountered in the tumors of 14 (17%) and 21 (26%) of the 80 patients,
Transitional cell carcinoma (TCC) of the female urethra is a rare urological malignancy, and intracranial metastasis of this cancer has not yet been reported in the literature. This review is intended to present a case of multiple intracranial metast
The wall of the bladder is lined with several layers of cells called transitional cells. Cancer arising from these cells makes up more than 90% of all bladder cancers and these are referred to as transitional cell carcinomas. Because transitional cell carcinomas are the most common type of bladder cancer, the information in this section only addresses treatment of transitional cell cancer of the bladder. Bladder cancer occurs predominantly in elderly men and less frequently in women and younger men. Many bladder cancers are thought to be caused by exposure to cancer-causing agents that pass through the urine and come into contact with the bladder lining. The most important risk factor for bladder cancer is smoking, which increases risk by at least four-fold.[1]. The most common sign of bladder cancer is hematuria or blood in the urine, which will turn the urine rust or red in color.[2] Other signs of bladder cancer may include pain during urination and frequent urination. Most patients with ...
Background: Transitional cell carcinoma (TCC) originating from the renal pelvis with a venous tumor thrombus is a rare entity. However, clinicians should be aware of it because of its high malignancy and poor prognosis.Case presentationHere, we report three cases of pathologically confirmed TCC originating from the renal pelvis with extension into the renal vein or inferior vena cava (IVC). Of these patients, two are males and one is female (58~73 years old). Their main symptom is flank pain; besides, gross hematuria and weight loss is observed in one of the patients. Computed tomography (CT) scan of the first patient revealed multiple space-occupying lesions in the left renal pelvis and left medium and lower ureter with a tumor thrombus in the left renal vein. CT scan of the second patient revealed a right renal mass and extension into the IVC. Abdominal magnetic resonance imaging (MRI) of the third patient showed a soft tissue mass in the region of the left renal sinus, and the signal of the ...
The transitional cell carcinoma is a particularly unpleasant tumor of the urinary bladder. In dogs, it usually arises in the lower neck of the bladder, where it is virtually impossible to surgically remove, and causes a partial or complete obstruction to urination. Bloody urine and straining to urinate are typically the signs noted by the owner. We know that Shetland sheepdogs, West Highland White terriers, Beagles, and Scottish terriers seem to be predisposed breeds.
Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function Academic Article ...
In this unique presentation, panelists at the 2019 AUA Annual Meeting cover the management of non-muscle invasive urothelial carcinoma and the management of advanced and metastatic urothelial carcinoma while discussing key take-home messages from AUA2019 sessions.
Advanced/Metastatic Bladder Cancer:. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28:1850-5.. Bernard-Pierrot I, Brams A, Dunois-Larde C, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006;27:740-74.. Cancer Genome Atlas Research Network., Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007;75:831-42.. Gómez-Román JJ, Saenz P, ...
Scottish Terriers are at 18-fold greater risk of developing urinary bladder cancer (invasive transitional cell carcinoma [TCC]) compared with other breeds. TCC is an aggressive tumor, and survival rates are poor. Most TCC of the bladder cannot be removed surgically and is resistant to chemotherapy. The best approach to reduce morbidity and mortality from bladder cancer in Scottish Terriers is to prevent its occurrence. The primary objective this epidemiological study is to identify host (genetic), agent, and environmental factors that increase or decrease the risk of TCC. A case control study is proposed in which Scottish Terriers of comparable ages with or without TCC will be compared. Using medical records and questionnaire responses from owners, the primary risk factors studied will include: (1) exposure to insecticides, particularly the new generation flea control products and lawn chemicals, (2) exposure to side stream cigarette smoke, (3) prior use of cyclooxygenase (cox) inhibiting drugs, a
Dilatated kidney caused by a transitional carcinoma with a tumor in the ureter and tumor nodules in the renal collecting system CT. ...
and one of the Primary Investigators of the trial. "These data support this unique approach to cancer treatment, which aims to improve standard of care therapy by targeting Hsp27, an important mechanism through which cancer develops resistance to treatment.". Apatorsen is designed to inhibit production of heat shock protein 27 (Hsp27), which increases with cancer treatment as well as with tumor stage and grade. High levels of Hsp27 contribute to cancer cell survival, proliferation and migration and also play a role in dampening a cancer patients immune function. Borealis-1 enrolled approximately 180 patients with documented metastatic or locally inoperable transitional cell carcinoma (TCC) of the urinary tract who had not previously received chemotherapy for metastatic disease and were not candidates for potentially curative surgery or radiotherapy. Patients were randomized to receive standard chemotherapy (gemcitabine/cisplatin) in combination with apatorsen at two dose levels (600 mg and 1000 ...
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as BCG and sargramosti
FINAL DIAGNOSIS:. HIGH-GRADE UROTHELIAL CARCINOMA WITH PLASMACYTOID, MICROPAPILLARY AND GLANDULAR DIFFERENTIATION.. DISCUSSION:. This tumor is a poorly differentiated invasive carcinoma, which shows glandular and divergent patterns of differentiation. There is no discrete papillary urothelial carcinoma component or urothelial carcinoma in situ. The tumor shows undifferentiated plasmacytoid histology, glandular differentiation and solid sheet-like architecture (similar to high-grade urothelial carcinoma). Because of the divergent differentiations, the possibility of a metastasis from a primary (like breast or stomach) was considered but was clinically unlikely (with negative mammography and endoscopy). The immunohistochemical profile with the positivity of CK7 and CK20 supports the urothelial origin of this tumor.. A micropapillary variant of transitional cell carcinoma (TCC) was first described in 1994 by Amin et al (1). Four morphological features were described as being distinct to this ...
Top 10 cancers for 11759665_a_at (Homo sapiens, Affymetrix Probeset): ovary, granulosa cell tumor, malignant, metastatic, temporal lobe, astrocytoma, NOS, kidney, collecting duct carcinoma, unstated behavior, frontal lobe, mixed glioma, temporal lobe, mixed glioma, skin, basal cell carcinoma, NOS, frontal lobe, oligodendroglioma, NOS, other / unspecified urinary organs, cerebrum, glioblastoma, NOS, renal pelvis, papillary transitional cell carcinoma
Combined gemcitabine and cisplatin (GC) treatment is a first line chemotherapy for bladder cancer. However, acquired resistance to GC has been a major problem. To address the mechanism of gemcitabine resistance, and to identify potential biomarkers or target proteins for its therapy, we aimed to identify candidate proteins associated with gemcitabine resistance using proteomic analysis. We established gemcitabine‑resistant human bladder cancer cell lines (UMUC3GR and HT1376GR) from gemcitabine‑sensitive human bladder cancer cell lines (UMUC3 and HT1376). We compared the protein expression of parental and gemcitabine‑resistant cell lines using isobaric tags for relative and absolute quantification (iTRAQ) and liquid chromatography tandem mass spectrometry. Among the identified proteins, ethylmalonyl‑CoA decarboxylase (ECHDC1) expression was significantly increased in both of the gemcitabine‑resistant cell lines compared to the respective parental cell lines. Silencing of ECHDC1 reduced ...
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Human Bladder Tumor lysate \ HTL-1325 for more molecular products just contact us
The test has a sensitivity of 90 percent and a specificity of 78 percent. Interference with the test (causing false positives) occurs with marked glucosuria (4+), heavy proteinuria (4+) or pyuria/hematuria (>30-40 WBC or RBC/hpf). Therefore a negative test has an accurate negative predictive value of 95 percent, but a positive test result would mean that further evaluation is indicated to rule-in or rule-out neoplasia ...
In the United States, there are millions more owned cats than owned dogs, yet cats visit veterinarians less frequently than dogs. A major reason is that it is very stressful to take cats to the veterinary practice and often owners believe their cat doesnt need routine check-ups for wellness and preventive care. The Cat Friendly Practice® (CFP) program, created by expert feline practitioners, provides a solution to this trend and provides an opportunity for veterinary practices to elevate care for cats and reduce the stress during the visit ...
Imaging features are consistent with a bladder tumour, most likely a transitional cell carcinoma. The patient was submitted to a transurethral resection of the bladder tumour (TURBT). MICROSCOPIC DESCRIPTION: The bladder biopsy shows features...
In the present study we demonstrated for the first time that, Pim-1 was increased in human bladder cancer epithelium as compared with that in normal bladder tissue. When the tumors were stratified by Non-invasive and invasive, a statistically significant increase of Pim-1 expression was found in the subgroup of invasive tumor when compared with that in the Non-invasive tumor. Pim-1 was also detected in all human bladder cancer cell lines tested in our study. Knockdown Pim-1 led to decreased phosphorylation of Bad and reduced expression of Bcl-2. Furthermore, downregulation of Pim-1 inhibited the bladder cancer cells growth and sensitized them to chemotherapy in vitro. Further evaluation of the prognostic significance of Pim-1 in a larger cohort with sufficient follow-up times will allow better understand of the clinical significance of Pim-1.. Overexpression of the Pim-1 protein has been reported in hematolymphoid malignancies and solid cancers [4, 5]. Pim-1 has been asserted to promote ...
Several lymphangiogenic factors, such as vascular endothelial growth factors (VEGFs), have been found to drive the development of lymphatic metastasis in bladder cancer (BCa).Here, we have analyzed the gene expression of lymphangiogenic factors in tissue specimens from 12 non-muscle invasive bladder cancers (NMIBC) and 11 muscle invasive bladder cancers (MIBC), considering tumor and tumor-adjacent normal bladder areas obtained from the same organs. We then compared the results observed in patients with those obtained after treating human primary bladder microvascular endothelial cells (MEC) with either direct stimulation with VEGF-A or VEGF-C or by co-culturing (trans-well assay) MEC with bladder cancer cell lines varying in VEGF-A and VEGF-C production based on tumor grade ...
B83 The purpose of this research project was to determine the efficacy of the cyclooxygenase (COX) and lipoxygenase (LOX) inhibitors, alone or in combination, to prevent OH-BBN-induced urinary bladder cancers in female Fischer-344 rats. In this OH-BBN-induced rat model, the bladder cancers are primarily transitional cell carcinomas which are mostly papillary and slowly growing. The rats were treated for 8 weeks with OH-BBN beginning at 49 days of age, then treated with chemopreventive agents and followed for an additional 6-7 months for the appearance of urinary bladder cancers. Beginning one week following the last OH-BBN administration and continuing until the end of the study, celecoxib (a COX2 inhibitor) was administered at 500 mg/kg diet, zileuton (a LOX inhibitor) at 1200 mg/kg diet, naproxen (a nonspecific COX inhibitor) at 200 or 400 mg/kg diet, aspirin (a COX1 inhibitor) at 300 and 3000 mg/kg diet, and caffeic acid (a LOX inhibitor) at 8 and 16 grams/kg diet. At the end of the study ...
Immunotherapy is one of many potential treatment options for bladder cancer. This quick guide can help you determine if its right for you.
Teaching Files with CT Medical Imaging and case studies on Anatomical Regions including Adrenal, Colon, Cardiac, Stomach, Pediatric, Spleen, Vascular, Kidney, Small Bowel, Liver, Chest | CTisus
Of particular importance is the identification of безболевого appearance of blood in the urine, which is associated with the ability to detect early-stage bladder tumors. Risk factors for the development of bladder cancer are Smoking and prolonged contact with aromatic hydrocarbons. It occurs most often transitional cell cancer of the bladder. More rare tumor of the bladder include adenocarcinoma (arising from урахуса) and squamous cell carcinoma (associated with chronic inflammation of the bladder or schistosomiasis ...
meta- and para-Cresidine (technical grades) were tested in mice and rats by dietary administration. In the only experiment in rats with meta-cresidine, it produced an increased incidence of transitional-cell carcinomas of the urinary bladder in males. The results of the study in mice were inconclusive. para-Cresidine produced malignant tumours of the urinary bladder in both mice and rats, olfactory neuroblastomas in rats of both sexes and liver tumours in male rats; it also produced nasal cavity tumours in male mice and liver-cell tumours in female mice.. Technical-grade meta-cresidine was not mutagenic to Salmonella typhimurium or Escherichia coli. para-Cresidine was mutagenic to S. typhimurium after metabolic activation. ...
On Aug 02, 2018 4:37 PM orchestra47 wrote: Hello Everyone out there with Stage 4 TCC,. I have Lynch Syndrome and was diagnosed with bilateral TCC into both renal pelvis, in Jan 2009. After replacement of both ureters with illeal, my right kidney was saved. Flash forward six months latyer and I had mets in liver, lungs, pelvis and left kidney. I was given 2 years to live. I was treated with carboplatin and gemzar for 5 months to help prolong my life. It is now 2018 and my oncologist at MD Anderson said that I am cured. She has no idea why I was spared and said shed not heard of anyone surviving liver mets with stage 4 bilateral TCC. I used a totally integrated therapy and had (have) an aggressive will to live. I have survived 5 cancers so far, and continue to cycle, work out, and be optimistic about life. By the way, Ive just celebrated my 71st birthday! I have a minimal support group and rely on my faith and will to live. I would be happy to correspond with anyone facing this horrid disease, ...
TY - JOUR. T1 - The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder. AU - Cho, Kang Su. AU - Seo, Joo Wan. AU - Park, Sung Jin. AU - Lee, Young Hoon. AU - Choi, Youngdeuk. AU - Cho, Namhoon. AU - Yang, Seung Choul. AU - Hong, Sung Joon. PY - 2009/5/1. Y1 - 2009/5/1. N2 - Purpose: We evaluated the incidence and risk factors for urethral recurrence following radical cystectomy and urinary diversion in transitional cell carcinoma. Patients and Methods: A retrospective review was performed of the 412 consecutive patients who underwent radical cystectomy and urinary diversion for transitional cell carcinoma of the bladder between 1986 and 2004. A total of 294 patients were enrolled in this study. We investigated the impact of various clinical and pathological features on urethral recurrence by univariate and multivariate analysis. Results: Urethral recurrence developed in 13 patients (4.4%) and the 5-year urethral ...
Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer Adenosine triphosphate;chemotherapy response assay;superficial bladder cancer; Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was
Background: Aberrant methylation of genes is one of the most common epigenetic modifications involved in the development of urothelial carcinoma. However, it is unknown the predictive role of methylation to contralateral new upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). We retrospectively investigated the predictive role of DNA methylation and other clinicopathological factors in the contralateral upper tract urothelial carcinoma (UTUC) recurrence after radical nephroureterectomy (RNU) in a large single-center cohort of patients.. Methods: In a retrospective design, methylation of 10 genes was analyzed on tumor specimens belonging to 664 consecutive patients treated by RNU for primary UTUC. Median follow-up was 48 mo (range: 3-144 mo). Gene methylation was accessed by methylation-sensitive polymerase chain reaction, and we calculated the methylation index (MI), a reflection of the extent of methylation. The log-rank test and Cox regression were used to identify ...
TY - JOUR. T1 - Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma. T2 - Subanalysis of the Japanese Urological Association multi-institutional national database. AU - Miyazaki, Jun. AU - Nishiyama, Hiroyuki. AU - Fujimoto, Hiroyuki. AU - Ohyama, Chikara. AU - Koie, Takuya. AU - Hinotsu, Shiro. AU - Kikuchi, Eiji. AU - Sakura, Mizuaki. AU - Inokuchi, Junichi. AU - Hara, Tomohiko. AU - Kanayama, Hiro omi. AU - Miki, Tsuneharu. AU - Suzuki, Kazuhiro. AU - Eto, Masatoshi. AU - Nakanishi, Hiroyuki. AU - Fukumori, Tomoharu. AU - Naito, Seiji. PY - 2015/11/1. Y1 - 2015/11/1. N2 - Objectives: To examine the influence of smoking history on the diagnosis and other tumor characteristics of upper tract urothelial carcinoma in Japan. Methods: A total of 1509 patients with upper tract urothelial carcinoma who were diagnosed in 2005 from 348 Japanese institutions were registered using the multi-institutional national database of the Japanese Urological Association and included in ...
TY - JOUR. T1 - Assessment of the Minimum Number of Lymph Nodes Needed to Detect Lymph Node Invasion at Radical Nephroureterectomy in Patients With Upper Tract Urothelial Cancer. AU - Roscigno, Marco. AU - Shariat, Shahrokh F.. AU - Freschi, Massimo. AU - Margulis, Vitaly. AU - Karakiewizc, Pierre. AU - Suardi, Nazareno. AU - Remzi, Mesut. AU - Zigeuner, Richard. AU - Bolenz, Christian. AU - Kikuchi, Eiji. AU - Weizer, Alon. AU - Bensalah, Karim. AU - Sagalowsky, Arthur. AU - Koppie, Theresa M.. AU - Raman, Jay. AU - Fernández, Mario. AU - Ströbel, Philipp. AU - Kabbani, Wareef. AU - Langner, Cord. AU - Wheat, Jeffery. AU - Guo, Charles C.. AU - Kassouf, Wassim. AU - Haitel, Andrea. AU - Wood, Christopher G.. AU - Montorsi, Francesco. PY - 2009/11/1. Y1 - 2009/11/1. N2 - Objectives: To determine whether a minimum number of lymph nodes (LNs) exist to detect lymph node invasion (LNI) in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Methods: The study ...
There was exciting news in the field of bladder cancer treatment at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA. Speaking from the meeting, Alison Birtle, MRCP, FRCR, MD, of Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK, discusses the findings from the POUT trial (NCT01993979), a Phase III randomized study that determined the efficacy and the safety of adjuvant chemotherapy following radical nephroureterectomy, as well as its effect on the quality of life, for patients with upper tract urothelial carcinoma (UTUC). With such promising data from the POUT trial, Dr Birtle expresses her hopes of adjuvant chemotherapy becoming the standard of care for patients with UTUC.
Hepatocellular carcinoma Neoplasm of ovary Small cell lung cancer Renal cell carcinoma Malignant melanoma of skin Papillary renal cell carcinoma, sporadic Carcinoma of gallbladder Colorectal Neoplasms Ovarian Neoplasms Ovarian Serous Cystadenocarcinoma Adenocarcinoma of prostate Squamous cell carcinoma of lung Glioblastoma Transitional cell carcinoma of the bladder Uterine Carcinosarcoma Pancreatic adenocarcinoma Adenocarcinoma of lung Uterine cervical neoplasms Squamous cell carcinoma of the head and neck Neoplasm of breast Adenocarcinoma of stomach Neoplasm of brain Malignant neoplasm of body of uterus Brainstem glioma Oesophageal carcinoma Nasopharyngeal Neoplasms Carcinoma of colon Epidermal nevus Malignant melanoma ...
Prostate cancer, radical prostatectomy, benign prostatic disease - BPH, stone disease, endourology, HIFU - high intensity focused ultrasound - for prostate cancer, laparoscopic nephrectomies, laparoscopic adrenalectomies, keyhole kidney stone surgery - PCNL - percutaneous nephrolithotomy, Holmium laser for stones and transitional cell carcinoma - TCC, RARP - robotically assisted radical prostatectomy, transperineal template biopsy ...
I. Management of invasive transitional cell human bladder carcinoma. II. Fluorescent in situ hybridization Comets for the ... A sample of cells, either derived from an in vitro cell culture or from an in vivo test subject is dispersed into individual ... Only the DNA of the cell remains, and unravels to fill the cavity in the agarose that the whole cell formerly filled. This ... The aqueous salt disrupts proteins and their bonding patterns within the cell as well as disrupting the RNA content of the cell ...
... is usually transitional cell carcinoma. Transitional cell carcinoma is "a common cause of ureter cancer and ... Of the total, 1,251 (94%) were transitional cell carcinoma of the papillary type. "Five-year relative survival rates from ... 251-262, retrieved 18 October 2013 Transitional Cell Cancer (Kidney/Ureter), National Cancer Institute Urethral Cancer, ... Transitional Cell Cancer (Kidney/Ureter), National Cancer Institute. ...
The most common type is transitional cell carcinoma. Other types include squamous cell carcinoma and adenocarcinoma. Diagnosis ... 90% of bladder cancers are transitional cell carcinoma. The other 10% are squamous cell carcinoma, adenocarcinoma, sarcoma, ... April 2009). "Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the ... "A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette-Guérin for Transitional-Cell Carcinoma ...
Superior Vena Cava Syndrome due to metastatic transitional cell carcinoma". Asian Cardiovasc Thorac Ann. 8: 280-2. Koirala B ( ...
Bladder cancer - the most common type is transitional cell carcinoma. Urodynamic testing can help to explain the symptoms. In ... The inner side of the bladder is lined with a mucosal membrane consisting of a surface glycocalyx that protects the cells ... Anatomy of the male bladder, showing transitional epithelium and part of the wall in a histological cut-out. The detrusor ... beneath it from urine, the urothelium (a form of transitional epithelium), a basement membrane, and the lamina propria. The ...
Raman, JD; Scherr, DS (2007). "Management of patients with upper urinary tract transitional cell carcinoma". Nature Clinical ... Effective Tumor Immunotherapy in Transitional Cell Carcinoma of the Bladder. 2005-2007 Career Development Award. Kidney Urology ... in transitional cell carcinoma of the bladder". Clinical Cancer Research. 11 (24 Pt 1): 8570-6. doi:10.1158/1078-0432.CCR-05- ... "Hand-Assisted Laparoscopic Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma". JSLS. 10 (4): 432-8. PMC ...
Ward AM (July 1971). "Glandular metaplasia and mucin production in transitional cell carcinomas of bladder". J. Clin. Pathol. ...
"Abnormal selective cytology predicts tumor recurrences in upper tract transitional cell carcinoma treated with endoscopic laser ... "Hand-Assisted Laparoscopic Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma". JSLS. 10 (4): 432-438. PMC ... for patients undergoing ureteroscopic biopsy and laser tumor ablation of upper tract transitional cell carcinoma". Urology. 66 ... GCO 03-0962(2). An Open Label, Single Arm Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 ( ...
"BCG Immunotherapy for Transitional-Cell Carcinoma in Situ of the Bladder". Retrieved 26 September 2016. "A technique for ...
2003). "High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma". Jpn. J. Cancer Res. 93 (5): 523- ... 2004). "Molecular cloning and expression of uroplakins in transitional cell carcinoma". Adv. Exp. Med. Biol. 539 (Pt A): 33-46 ... "Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells ... Cell. 13 (12): 4221-30. doi:10.1091/mbc.E02-04-0211. PMC 138628 . PMID 12475947. Strausberg RL, Feingold EA, Grouse LH, et al ...
"PTCH gene mutations in invasive transitional cell carcinoma of the bladder". Oncogene. 17 (9): 1167-72. doi:10.1038/sj.onc. ... basal-cell carcinoma, pancreatic cancer, and prostate cancer. As such, SMO is an attractive cancer drug target, along with the ... a smoothened receptor inhibitor for the treatment of basal-cell carcinoma, being investigated for the treatment of other types ... "Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central ...
Production of trophoblastic hormones by transitional cell carcinoma of the bladder: association to tumor stage and grade". Hum ... cervical carcinoma, gastric carcinoma, squamous-cell carcinoma of the oral cavity and oropharynx, lung carcinoma, and ... "Concentration of free hCGb subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and ... "Colinear synthesis of an antigen-specific B-cell epitope with a promiscuous tetanus toxin T-cell epitope: a synthetic peptide ...
She was being treated for transitional-cell carcinoma, a form of cancer. Thorne died of bladder cancer in Concord, ...
2001). "Prostate stem cell antigen is overexpressed in human transitional cell carcinoma". Cancer Res. 61 (12): 4660-5. PMID ... 2007). "Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells". ... "Entrez Gene: PSCA prostate stem cell antigen". Gu Z, Thomas G, Yamashiro J, et al. (2000). "Prostate stem cell antigen (PSCA) ... "Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer". Proc Natl Acad Sci U S A. 95 (4): 1735-40 ...
Non-metastatic squamous cell carcinoma and transitional cell carcinoma are very rare in the endometrium. Squamous cell ... Histologically, TCCE resembles endometrioid carcinoma and is distinct from other transitional cell carcinomas. In contrast to ... Papillary serous carcinoma, clear cell carcinoma, and endometrioid carcinoma are the subtypes at the highest risk of recurrence ... distinct cell membranes. The p53 cell signaling system is not active in endometrial clear cell carcinoma. This form of ...
"Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma". PLoS One. 8 (12): e81348. doi: ... SPAG9 is a potential biomarker for early cervical carcinoma bladder cancer, and lung cancer. SPAG9 has been shown to interact ... This gene which is abundantly expressed in testicular haploid germ cells encodes a protein that is recognized by sperm- ... Extracellular signals are transduced into cells through mitogen-activated protein kinases. The structural organization of these ...
Rarer forms of tubal neoplasm include the leiomyosarcoma, and the transitional cell carcinoma. As the tumor is often enmeshed ... GOLDMAN JA, GANS B, ECKERLING B (November 1961). "Hydrops tubae profluens--symptom in tubal carcinoma". Obstet Gynecol. 18: 631 ... Vaginal discharge in fallopian tube carcinoma result from intermittent hydrosalphinx that is called as hydrops tubae profluens ... "Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube". Gynecol Oncol. UCSF. "Gynecologic Cancer: ...
He died on October 7, 2014 in Kathmandu, suffering from transitional cell carcinoma. "Dr AK Sharma, pioneer of modern surgery, ...
"Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study ... Cell. 127 (1): 185-97. doi:10.1016/j.cell.2006.07.037. PMID 17018285. "Entrez Gene: ERBB4 v-erb-a erythroblastic leukemia viral ... Cohen BD, Green JM, Foy L, Fell HP (Mar 1996). "HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence ... Culouscou JM, Plowman GD, Carlton GW, Green JM, Shoyab M (Sep 1993). "Characterization of a breast cancer cell differentiation ...
Types of urethral cancer include transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, and melanoma. Surgery is ... Cancer in this location is rare, and the most common type is papillary transitional cell carcinoma. The most common site of ... Anterior urethral cancer Carcinoma of the penis Ries, LAG; Young, JL; Keel, GE; Eisner, MP; Lin, YD; Horner, M-J, eds. (2007 ... Chemotherapy is sometimes used to destroy urethral cancer cells. It is a systemic urethral cancer treatment (i.e., destroys ...
Also note that the bladder wall is thickened due to possible transitional cell carcinoma. Large bowel (sigmoid colon) showing ...
"High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder". Cancer Res. 63: 7657-62. PMID ...
"Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma". J Int Med Res. ... The encoded protein may play a role in the establishment and function of specific cell-cell connections in the brain. PCDH17 ... Cell Res. 261 (1): 13-8. doi:10.1006/excr.2000.5039. PMID 11082270. Wu Q, Maniatis T (2000). "Large exons encoding multiple ...
Less common tumors are malignant Brenner tumor and transitional cell carcinoma of the ovary. Sex cord-stromal tumor, including ... Germ cell tumors tend to occur in young women (20's-30's) and girls. Whilst overall the prognosis of germ cell tumors tend to ... Germ cell tumor accounts for approximately 30% of ovarian tumors but only 5% of ovarian cancers, because most germ cell tumors ... estrogen-producing granulosa cell tumor and virilizing Sertoli-Leydig cell tumor or arrhenoblastoma, accounts for 8% of ovarian ...
2004). "Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder". Int. J. ... "Tmod3 regulates polarized epithelial cell morphology". J. Cell Sci. 120 (Pt 20): 3625-32. doi:10.1242/jcs.011445. PMID 17928307 ... doi:10.1016/j.cell.2006.09.026. PMID 17081983. Fischer RS, Yarmola EG, Weber KL, et al. (2007). "Tropomodulin 3 binds to actin ... Cell Biol. 6 (2): 97-105. doi:10.1038/ncb1086. PMID 14743216. Fischer RS, Fritz-Six KL, Fowler VM (2003). "Pointed-end capping ...
2004). "Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder". Int. J. ... Cell Res. 209 (2): 388-91. doi:10.1006/excr.1993.1325. PMID 8262158. Lench NJ, Telford EA, Andersen SE, et al. (1997). "An EST ... 2004). "The interaction between E-tropomodulin and thymosin beta-10 rescues tumor cells from thymosin beta-10 mediated ... Cell Sci. 107 (6): 1633-9. PMID 7962203. Sung LA, Lin JJ (1994). "Erythrocyte tropomodulin binds to the N-terminus of hTM5, a ...
Small cell carcinoma is a very rare (1%[77]) type of prostate cancer that cannot be diagnosed using the PSA.[77][78] As of 2009 ... lo Prostate Cancer Cell Population Harbors Self-Renewing Long-Term Tumor-Propagating Cells that Resist Castration". Cell Stem ... "Small-cell carcinoma of the prostate". Journal of the Royal Society of Medicine. 90 (6): 340-1. PMC 1296316 . PMID 9227387.. ... The upregulation of BCL-2 after androgen ablation in prostate carcinoma cell lines and in a castrated-male rat model further ...
2004). "Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder". Int. J. ... Cell Sci. 109 (9): 2299-310. PMID 8886980. Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and ...
Raman, Jay D. ; Scherr, Douglas S. / Management of patients with upper urinary tract transitional cell carcinoma. In: Nature ... Raman, J. D., & Scherr, D. S. (2007). Management of patients with upper urinary tract transitional cell carcinoma. Nature ... Raman, JD & Scherr, DS 2007, Management of patients with upper urinary tract transitional cell carcinoma, Nature Clinical ... Management of patients with upper urinary tract transitional cell carcinoma. / Raman, Jay D.; Scherr, Douglas S. ...
... are prognostic factors of overall survival for patients with invasive upper urinary tract transitional cell carcinoma (UUT-TCC ... Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. ... Aged, Carcinoma, Transitional Cell, Female, Humans, Kidney Neoplasms, Male, Microsatellite Repeats, MutS Homolog 2 Protein, ... Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. ...
The recommended definition of microscopic hematuria is three or more red blood cells per high-power microscopic field in ... In patients with microscopic hematuria, imaging can be used to detect renal cell carcinoma, transitional cell carcinoma in the ... Transitional cell carcinoma of the renal pelvis: a retrospective look at CT staging with pathologic correlation. Radiology. ... Voided urinary cytology is recommended in all patients who have risk factors for transitional cell carcinoma (Table 1).4 This ...
UPPER URINARY-TRACT ; TRANSITIONAL-CELL-CARCINOMA ; INVASIVE BLADDER-CANCER ; PROMOTER HYPERMETHYLATION ; RENAL PELVIS ; TUMORS ... Methylation Upper Tract Urothelial Carcinoma Contralateral Recurrence Radical Nephroureterectomy Predictors 刊名. JOURNAL OF ... 3.Peking Univ, Canc Hosp & Inst, Minist Educ, Dept Cell Biol,Key Lab Carcinogenesis & Translat, Beijing 100142, Peoples R China ... However, it is unknown the predictive role of methylation to contralateral new upper tract urothelial carcinoma (UTUC) after ...
The third possibility is that of signet ring cell carcinoma arising from metaplastic transitional cell carcinoma [4, 10-14]. ... normal transitional cell carcinoma will reveal signet ring cells in many cases and the exact percentage of signet ring cells ... Most patients present in middle-age with symptoms indistinguishable from the much more common transitional cell carcinoma of ... Those consisting of a mix of signet-ring cells and transitional cells are more likely to be of primary bladder origin [1]. Also ...
Drugs & Diseases , Radiology , Transitional Cell Carcinoma Imaging Q&A How are transitional cell carcinomas (TCCs) staged?. ... encoded search term (How are transitional cell carcinomas (TCCs) staged?) and How are transitional cell carcinomas (TCCs) ... Transitional cell carcinoma of the upper urinary tract: staging by MRI. Abdom Imaging. 1995 Jul-Aug. 20(4):365-7. [Medline]. ... A provisional diagnosis of transitional cell carcinoma was made. Subsequent investigations and the course of events proved that ...
Transitional cell carcinoma of the ovary "transitional cell carcinoma" at Dorlands Medical Dictionary Colin P, Koenig P, ... Micrograph of urethral urothelial cell carcinoma. H&E stain. Transitional cell carcinoma (TCC) can be very difficult to treat. ... Transitional cell carcinoma (TCC) also urothelial carcinoma (UCC), is a type of cancer that typically occurs in the urinary ... Njinou Ngninkeu B, Lorge F, Moulin P, Jamart J, Van Cangh PJ (January 2003). "Transitional cell carcinoma involving the ...
Transitional Cell Carcinoma Imaging Q&A Which ultrasonography findings are characteristic of transitional cell carcinoma (TCC)? ... Transitional cell carcinoma of the upper urinary tract: staging by MRI. Abdom Imaging. 1995 Jul-Aug. 20(4):365-7. [Medline]. ... A provisional diagnosis of transitional cell carcinoma was made. Subsequent investigations and the course of events proved that ... The histologic diagnosis was a right renal pelvis neurofibroma and a bladder transitional cell carcinoma. ...
... we analyzed the proteomic profiling of transitional cell carcinoma (TCC) cell lines to search for novel biomarkers for human ... Transitional cell carcinoma (TCC) is the one of the most commonly observed types of cancer globally. The identification of ... Transitional cell carcinoma of the bladder, the second most common urologic malignancy, is amenable to early diagnosis. This ... Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan. The carcinogenesis ...
Transitional cell carcinoma of the ovary, abbreviated TCC of the ovary, is a rare type of ovarian cancer that has an appearance ... Apr 2004). "Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis ... It is not related urothelial carcinoma. It is in the transitional cell category of ovarian tumours which also includes ... Brenner tumour Tazi, EM.; Lalya, I.; Tazi, MF.; Ahellal, Y.; Mrabti, H.; Errihani, H. (2010). "Transitional cell carcinoma of ...
Transitional cell carcinoma of the urinary bladder is a malignancy that metastasizes frequently to lymph nodes including the ... Mediastinal metastases from transitional cell carcinoma of the bladder either are asymptomatic or may more commonly produce the ... S. S. Dhillon, D. Singh, B. Dass, and C. R. Schaub, "Transitional cell carcinoma manifesting as acute cor pulmonale: cause of ... We report the case of a 59-year-old man with metastatic transitional cell carcinoma for whom mediastinal lymphadenopathy led to ...
Treatment for Murine Transitional Cell Carcinoma http://www.chiro.org/nutrition/ABSTRACTS/Allium_Sativum_Garlic_Treatment.shtml ... Murine Transitional Cell Carcinoma This section is compiled by Frank M. Painter, D.C.. Send all comments or additions to: ... further investigation and suggests that AS may provide a new and effective form of therapy for transitional cell carcinoma of ... is the most effective treatment for superficial bladder carcinoma, but treatment-related toxicity may limit its use in some ...
Transitional cell carcinoma can be distinguished from adenocarcinoma and carcinoma endometriode exclusively for its ... Transitional cell carcinoma has its origin at the level of the periurethral ducts in the area of the junction of the ... Transitional cell carcinoma is a rare neoplasm with an reported incidence of 2%. It is biologically different from ... Various therapies have been used to treat transitional cell carcinoma but with poor results. Surgical treatment is still today ...
Urothelial (Transitional Cell) Carcinoma. Urothelial carcinoma (formerly known as transitional cell carcinoma) is a cancer ... People with urothelial carcinoma of the kidney often have the same symptoms as patients with renal cell cancer. The most ... Chemotherapy is sometimes used in the treatment of urothelial carcinoma. Follow up is important because urothelial carcinoma is ... The cells use to be called transitional because they can stretch and change shape without breaking. ...
Ninety percent of bladder cancers are transitional cell carcinomas. Other types are squamous cell carcinoma, adenocarcinoma, ... Pelvic renal transitional cell carcinoma represents about 10% of all renal carcinomas. ... About 10% of transitional cell carcinomas of the ureteral tract arise in the renal pelvis. Tumors arising in the renal pelvis ... Transitional cell carcinoma arises from the epithelial layer found in the renal pelvis, ureter, or bladder. They are noted for ...
Epidemiology Upper urinary tract transitional cell carcinomas (TCCs) are relatively rare, accounting for 5-7% of all renal ... Background of Upper Tract Transitional Cell Carcinoma. Epidemiology. Upper urinary tract transitional cell carcinomas (TCCs) ... Komatsu H, Tanabe N, Kubodera S, Maezawa H, Ueno A. The role of lymphadenectomy in the treatment of transitional cell carcinoma ... Miyake H, Hara I, Gohji K, Arakawa S, Kamidono S. The significance of lymphadenectomy in transitional cell carcinoma of the ...
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment. Official Title ICMJE H-16848 ... Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment. This study has been completed ... Phase II Pilot Study With Correlative Markers of Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous ... Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006 Jun ...
Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of ... Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014: Order report by calling Rnrmarketsresearch. ... The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma) ... It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma ...
Ninety percent of bladder cancers are transitional cell carcinomas. Other types are squamous cell carcinoma, adenocarcinoma, ... Urothelial Cell Carcinoma Linked to High Albumin Excretion *Broccoli Sprout Extract in Treating Patients With Transitional Cell ... Pelvic renal transitional cell carcinoma represents about 10% of all renal carcinomas. ... About 10% of transitional cell carcinomas of the ureteral tract arise in the renal pelvis. Tumors arising in the renal pelvis ...
Carcinoma, Transitional Cell: A malignant neoplasm derived from transitional epithelium, occurring chiefly in the urinary ... Transitional cell carcinomas are graded 1 to 3 or 4 according to the degree of anaplasia, grade 1 appearing histologically ...
... in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy. Trial Phase:. Phase 2. Minimum Age:. 18 Years ... in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy. The Study Drug:. Erlotinib hydrochloride is ... focal on pathology); Small cell carcinoma; 3-D mass on exam under anesthesia (EUA);. Lymphovascular invasion; Hydronephrosis ( ... the case for small cell variant which is traditionally treated with cytoreductive. chemotherapy. Patients with small cell who ...
... cancer arising from the transitional epithelium - the highly stretchable lining of the urinary tract system - of the kidney, ... Transitional cell carcinoma (TCC) is a malignant (aggressive) and metastasizing (spreading) ... Transitional Cell Carcinoma of the Renal, Bladder and Urethra in Dogs. Transitional cell carcinoma (TCC) is a malignant ( ... Transitional Cell Carcinoma of the Urinary Tract in Dogs. 3 min read ...
Transitional Cell Carcinoma of the Urinary Tract in Dogs. 3 min read ... Also referred to as a UTI; a medical condition of the urinary tract and system in which the cells are damaged by microorganisms ... A covering of cells that turns into the outermost layer of skin and covers the body ...
Transitional cell carcinoma (TCC) is the most common type of bladder cancer in dogs. Dr. Mason is actively researching ... Canine Transitional Cell Carcinoma. Transitional cell carcinoma (TCC) is the most common type of bladder cancer in dogs. Most ... cancer active transitional cell carcinoma TCC Mason TCC carcinoma Mason Active canine carcinoma canine bladder cancer bladder ... TRANSITIONAL CELL CARCINOMA - Clinical Trial Using Immunotherapy For Female Dogs With Bladder Cancer. A modified Listeria ...
  • To account for intermittent positive tests for hematuria in patients with urologic malignancies, 6 , 9 one group of investigators 10 proposed that patients with more than three red blood cells per high-power field from two of three properly collected urine specimens should be considered to have microhematuria and, thus, should be evaluated appropriately. (aafp.org)
  • How are transitional cell carcinomas (TCCs) staged? (medscape.com)
  • The 1973 WHO grading system for TCCs (papilloma, G1, G2 or G3) is most commonly used despite being superseded by the 2004 WHO grading (papillary neoplasm of low malignant potential [PNLMP], low grade, and high grade papillary carcinoma). (wikipedia.org)
  • However, several invasive TCCs exhibited the strongest intensity of Cox-2 staining in the invading cells, whereas other parts of the tumor were virtually negative. (nih.gov)
  • Although 95% of cases of interstitial nephritis present with hematuria, they also present with white cells in the urine and with white cell casts and are accompanied with fever, rash, arthralgias, and peripheral eosinophilia. (oncologynurseadvisor.com)
  • A urinalysis is an analysis of urine including the a brief chemical analysis and a microscopic examination of the cells contained in the sample. (marvistavet.com)
  • In bladder cancer, cancerous cells develop in the organ that collects urine from the kidneys before eliminating it from the body through urination. (medicalnewstoday.com)